Medifast, Inc. MED R2K

Q: What is the current share price of Medifast, Inc. (MED)?

As of 2026-07-14 21:23 PDT, Medifast, Inc. (MED) trades at $10.61 on NYSE. Its 52-week range is $9.53 to $15.21.

Q: What is the market capitalisation of MED?

Medifast, Inc. (MED) has a market capitalisation of $117.97M on NYSE.

Q: What is the P/E ratio of MED?

MED trades at a trailing price-to-earnings (P/E) ratio of -5.83. The industry average P/E is 22.82. Its price-to-book (P/B) ratio is 0.62.

Q: What is the return on equity (ROE) of MED?

MED has a return on equity (ROE) of -9.80%. Its return on capital employed (ROCE) is -6.93%.

Q: Is MED a good stock to buy?

This page provides a data-driven analysis of Medifast, Inc. (MED), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Consumer Cyclical · Personal Services · United States

https://medifastinc.com

Company Profile ↓

$10.61

-26.01% 1Y

Mkt Cap$117.97M

P/E-5.83

P/B0.62

52W High$15.21

52W Low$9.53

Book Value$19.28

EPS (TTM)$-1.82

Company Overview

Medifast, Inc., through its subsidiaries, operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions to address weight loss in the United States. The company offers weight loss, weight management, and healthy living products comprising bars, cereals, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, soups, essential amino acid blends, whey protein, hot beverages, brownies, and mini meals under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories, as well as daily nutrient packs, including multivitamins, minerals, and omega-3 fatty acid supplements. It also provides lifestyle plans consisting of 5 & 1 Plan and 5 & 1 ACTIVE Plan, which provides a targeted reset of the body's metabolism by activating strong and targeted fat burn; Optimal Weight 4 & 2 & 1 Plan and Optimal Weight 4 & 2 ACTIVE Plan, which is designed for clients who want to continue eating all food groups or want a flexible meal plan to achieve a healthy weight; OPTAVIA Optimization Plan, a personalized approach to help clients' long-term weight management; and OPTAVIA GLP-1 Nutrition Support Plan, a nutritional companion to GLP-1 medication that allows clients to focus on weight loss without the stress of figuring out what to eat. In addition, the company offers metabolic synchronization, a science that reverses metabolic dysfunction through a targeted reset of the body's metabolism. It markets its products through point-of-sale transactions executed over an e-commerce platform. The company serves health and wellness consumers. The company was formerly known as Healthrite, Inc. and changed its name to Medifast, Inc. in May 2001. Medifast, Inc. was incorporated in 1980 and is headquartered in Baltimore, Maryland.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.08.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $385.79M (-36.0% YoY); net profit $-18.67M.
Trailing 12 Months Year-on-year growth — revenue -34.3%, earnings -993.0%.
5-Year Trend Long-term compounding — revenue CAGR 5.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	5.27%
1 Year:	-34.30%

Compounded Profit Growth

5 Years:	-
1 Year:	-992.97%

Stock Price Performance

1 Year:	-26.01%
6 Months:	-7.09%
3 Months:	-0.19%
1 Month:	-10.99%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 19% of range

$9.53 $15.21

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)40.17 · Neutral

Price Performance

1M-10.99%

3M-0.19%

6M-7.09%

1Y-26.01%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Trading 30.2% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-5.83

Industry PE

22.82

Forward P/E

-17.68

PEG Ratio

0.97

Book Value

$19.28

Price to Book

0.62

P/S

0.38

EV/EBITDA

7.76

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

5.27%

Profit 5Y

Revenue (YoY)

-34.30%

Earnings (YoY)

-992.97%

Profitability & Returns

ROCE

-6.93%

ROE

-9.80%

ROA

-4.33%

Profit Margin

-5.79%

Op Margin

-7.21%

Gross Margin

70.12%

EPS (Latest Qtr)

$-0.19

EPS (TTM)

$-1.82

Balance Sheet & Liquidity

Debt/Equity

0.08

Quick Ratio

4.00

Current Ratio

4.80

Debt

$16.10M

Total Assets

$252.05M

Current Assets

Working Capital

Ownership

Promoter Holding

4.36%

Chg in Prom Hold

FII / Inst Holding

85.19%

Chg in FII Hold

-0.00%

Financial Snapshot

Enterprise Value

$117.97M

Total Revenue (TTM)

$346.10M

EBITDA

$-3.98M

Free Cash Flow

$4.41M

Operating Cash Flow

$3.72M

Shares Outstanding

11.12M

Gross Margin

70.12%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Consumer Cyclical).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	MED Medifast, Inc. R2K	10.61	-5.83	$117.97M	0.00%	-6.93%	-9.80%	5.27%	-
2	AMZN Amazon.com, Inc. NDXSPXAI	247.49	32.82	$2.66T	0.00%	16.60%	24.29%	11.73%	984.47%
3	TSLA Tesla, Inc. NDXSPXAI	396.18	360.16	$1.49T	0.00%	4.10%	4.90%	52.40%	39.39%
4	HD The Home Depot, Inc. SPX	337.74	23.97	$336.77B	2.84%	28.75%	128.38%	1.52%	-6.11%
5	BABA Alibaba Group Holding Limited AI	112.32	17.28	$269.47B	0.93%	4.16%	9.22%	5.62%	12.49%
6	MCD McDonald's Corporation SPX	268.94	22.17	$191.08B	2.61%	22.47%	-	0.92%	7.33%
7	TJX The TJX Companies, Inc. SPX	150.34	29.25	$166.08B	1.14%	21.26%	61.25%	6.84%	8.48%
8	BKNG Booking Holdings Inc. NDXSPX	174.85	23.04	$135.49B	0.97%	70.23%	-96.88%	16.93%	22.07%
9	SBUX Starbucks Corporation NDXSPX	106.17	81.05	$121.00B	2.41%	13.46%	-22.93%	7.93%	5.80%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	417.60M	453.33M	390.40M	348.98M	296.19M	235.87M	174.74M	168.56M	140.16M	115.73M	105.56M	89.41M	76.04M
Gross Profit	53.77M	53.17M	49.16M	45.22M	53.19M	53.23M	52.16M	47.08M	52.89M	57.61M	58.18M	59.13M	74.81M	88.80M	107.20M	109.09M	125.15M	140.71M	142.93M	128.07M	135.24M	159.30M	204.04M	199.24M	248.55M	293.71M	307.06M	302.29M	321.68M	282.85M	246.39M	210.72M	177.38M	127.29M	123.44M	105.67M	84.25M	76.64M	62.16M	51.76M
Operating Income	6.51M	8.66M	7.97M	-	6.27M	5.02M	8.95M	-	8.61M	11.31M	10.23M	-	14.68M	17.11M	17.47M	-	24.71M	27.36M	20.26M	-	23.53M	28.10M	44.56M	-	52.80M	61.43M	55.17M	55.09M	48.96M	48.16M	53.51M	38.71M	25.51M	7.94M	-7.88M	2.11M	-1.26M	-1.07M	-4.08M	-3.29M
Net Income	4.44M	6.25M	5.51M	3.86M	4.26M	3.40M	6.07M	4.11M	6.14M	7.58M	6.69M	7.31M	12.22M	14.13M	13.78M	15.65M	20.75M	21.38M	15.90M	19.88M	18.48M	21.93M	34.45M	27.99M	41.06M	46.96M	41.98M	41.78M	39.11M	36.16M	39.97M	30.28M	23.13M	8.32M	-8.15M	1.13M	-772.00K	2.48M	-2.26M	-2.12M
Diluted EPS	0.36	0.51	0.46	0.33	0.36	0.29	0.51	0.34	0.51	0.63	0.55	0.60	1.01	1.16	1.14	1.30	1.70	1.75	1.32	1.66	1.56	1.86	2.91	2.36	3.46	3.96	3.56	3.59	3.42	3.27	3.67	2.77	2.12	0.76	-0.75	0.10	-0.07	0.22	-0.21	-0.19

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	169.74M	257.55M	298.19M	318.57M	324.05M	285.29M	272.77M	274.53M	301.56M	501.00M	713.67M	934.84M	1.53B	1.60B	1.07B	602.46M	385.79M
Gross Profit	124.39M	192.47M	224.50M	235.91M	240.57M	209.21M	201.31M	205.66M	227.81M	379.90M	536.86M	697.82M	1.13B	1.14B	775.85M	444.62M	275.19M
Operating Income	18.50M	31.64M	27.38M	27.14M	38.41M	30.25M	28.68M	26.86M	39.63M	69.06M	91.04M	134.16M	216.24M	184.81M	126.40M	2.88M	-14.21M
Net Income	11.36M	19.61M	18.54M	15.88M	23.97M	13.18M	20.06M	17.84M	27.72M	55.79M	77.92M	102.86M	164.03M	143.57M	99.42M	2.09M	-18.67M
Diluted EPS	0.77	1.35	1.31	1.16	1.73	1.03	1.66	1.49	2.29	4.62	6.43	8.68	13.89	12.73	9.10	0.19	-1.70
R&D Expense	-	-	-	-	-	1.30M	1.80M	2.00M	1.50M	2.20M	2.70M	2.80M	4.40M	4.50M	4.60M	4.60M	4.30M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	94.06M	105.67M	130.25M	132.65M	115.91M	116.12M	121.22M	145.93M	169.43M	194.65M	276.08M	398.33M	316.21M	309.91M	284.21M	247.97M
Total Equity	34.07M	47.82M	71.96M	73.40M	90.79M	98.42M	80.48M	88.58M	96.02M	106.56M	109.11M	104.83M	157.25M	202.47M	155.04M	201.48M	210.11M	198.92M
Cash & Equivalents	973.00K	10.60M	17.16M	14.26M	39.94M	36.38M	24.46M	42.04M	52.44M	75.08M	81.36M	76.97M	163.72M	104.18M	87.69M	94.44M	90.93M	89.30M
Long Term Debt	-	-	4.65M	3.34M	3.11M	0	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	22.10M	32.26M	39.47M	34.23M	35.43M	27.53M	25.20M	37.35M	60.32M	89.82M	118.84M	195.85M	161.17M	108.43M	74.10M	49.05M
Current Liabilities	-	-	15.96M	20.26M	28.75M	27.10M	26.94M	23.56M	24.42M	37.14M	60.32M	79.39M	111.35M	169.83M	140.89M	92.30M	64.16M	42.96M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	19.16M	28.77M	34.87M	40.26M	42.36M	25.54M	29.41M	25.35M	43.24M	60.82M	84.26M	145.20M	94.55M	194.57M	147.66M	24.48M	6.86M
Investing Cash Flow	-8.62M	-23.54M	-16.87M	-11.66M	-22.60M	-2.52M	-189.00K	-2.04M	-3.16M	-1.20M	-6.33M	-1.28M	-29.06M	-11.41M	-61.05M	-26.52M	-7.93M
Financing Cash Flow	-908.00K	1.33M	-20.90M	-2.92M	-23.31M	-34.94M	-11.73M	-12.92M	-17.36M	-53.33M	-82.32M	-57.14M	-125.13M	-199.58M	-79.79M	-1.51M	-564.00K
Capital Expenditure	-5.12M	-12.05M	-14.27M	-8.13M	-11.39M	-7.02M	-2.82M	-2.88M	-3.24M	-4.94M	-10.06M	-5.89M	-34.21M	-16.68M	-6.48M	-7.45M	-5.61M
Free Cash Flow	14.04M	16.71M	20.60M	32.14M	30.97M	18.51M	26.59M	22.47M	39.99M	55.88M	74.20M	139.31M	60.34M	177.89M	141.17M	17.02M	1.25M
Share Buybacks	102.00K	35.00K	20.39M	2.76M	20.08M	33.89M	10.52M	-	-	30.00M	33.11M	5.00M	56.00M	126.44M	3.60M	0	0
Dividends Paid	-	-	-	-	-	-	-	11.89M	15.39M	23.16M	35.40M	53.19M	63.86M	71.62M	73.02M	715.00K	195.00K

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	73.3%	74.7%	75.3%	74.1%	74.2%	73.3%	73.8%	74.9%	75.5%	75.8%	75.2%	74.6%	73.9%	71.3%	72.4%	73.8%	71.3%
Operating Margin %	10.9%	12.3%	9.2%	8.5%	11.9%	10.6%	10.5%	9.8%	13.1%	13.8%	12.8%	14.4%	14.2%	11.6%	11.8%	0.5%	-3.7%
Net Margin %	6.7%	7.6%	6.2%	5.0%	7.4%	4.6%	7.4%	6.5%	9.2%	11.1%	10.9%	11.0%	10.7%	9.0%	9.3%	0.3%	-4.8%
ROE %	23.8%	27.3%	25.3%	17.5%	24.4%	16.4%	22.6%	18.6%	26.0%	51.1%	74.3%	65.4%	81.0%	92.6%	49.3%	1.0%	-9.4%
ROCE %	-	40.5%	32.1%	26.7%	36.4%	34.0%	31.0%	27.7%	36.4%	63.3%	79.0%	81.4%	94.6%	105.4%	58.1%	1.3%	-6.9%

Shareholding Pattern

Insiders

4.36%

Institutions

85.19%

Public Float

89.07%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	8.49%	944.45K	$10.38M
2	Renaissance Technologies, LLC	6.96%	773.71K	$8.50M
3	Steamboat Capital Partners, Llc	6.36%	707.59K	$7.78M
4	Charles Schwab Investment Management, Inc.	5.68%	631.54K	$6.94M
5	Vanguard Capital Management LLC	4.00%	444.47K	$4.88M
6	Dimensional Fund Advisors LP	3.25%	361.76K	$3.98M
7	Two Sigma Investments, LP	3.04%	338.16K	$3.72M
8	Morgan Stanley	2.93%	325.31K	$3.58M
9	Geode Capital Management, LLC	2.28%	253.31K	$2.78M
10	Man Group PLC	2.12%	236.21K	$2.60M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MED

Google News ue, 14 Jul 2026

A Look Back at Personal Care Stocks’ Q1 Earnings: Medifast (NYSE:MED) Vs The Rest Of The Pack - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQbG8tTDNCYVR0MzloQTRMaEdnNmMzYXU0Z28tNzA3OXByOGk1MEpNWXZ2VXl3NDBaSzl2NU15dXk3M1gxYzh6UEFlcEJ0OW00eUMyaXNWX3JRWENabl9zMjNzTDhZWWNUa3pUTmlUdXQ0RFZ3am9BOEQwMFNLNFNyd1R5SmVBQU5WbVBrZT…

Google News Fri, 10 Jul 2026

Medifast Inc (NYSE: MED) director details indirect fund-held share ownership in Form 3/A - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxNVE5XMGxlRWtYdTdLYWcwcno2Qk9vN0dPTkd4TEtweDhMY2ZIV3ZHa0RlR1Q2akJYZXRwMXpKdU03SE12OEJkZTVmcDhPTmVONTh2Wko4ajZ2RGxjbGhVeTMzc28tYXJBU1YyY0Y2OC1nX1ZQQms1eldCRWIzSGs4N0N0YnU3dDVFNy04Z2…

Google News Mon, 06 Jul 2026

3 Reasons MED is Risky and 1 Stock to Buy Instead - StockStory

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOSGFiUF9sVkZCLWRBWjc3UnJSTkxmSXl5VTVOYWVSSVRaRHRxVVNWOVBST195TUhxTnlRX2tjR3hVYW1oSjhnemJPdFJGYnJyU3hKYks0TXhEeWZGT2dvTFd5cURGYWFmNXd4RktzSkNHbUEzektRa1B5UnFfeElLN21YbTBDWHkwdENOc1…

Google News Fri, 01 May 2026

Medical Technology Stocks: Innovation Endures as Valuations Reset - AllianceBernstein

<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxOYnNxSEpGSzk5cm45ZE9KRUVqOTJ6VlQ4U0x3ckJrYnpPZWJvSUxlUWdGOUg5dXNzd085U1o4aWdzODJ2Yk1SNTRVaXZNVkRtQWd1d0F5VktkcFY5RkFEN0dlYkFoNnRFdGdsemZBUlhUMS1UelltLUwwelZZSnBxYTVNSWRia082dFlqd0…

Google News ue, 30 Dec 2025

Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025’s Largest Hong Kong Biotech IPO - Insilico Medicine

<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxQek9GUzR0Vl9RcHRLWlFXeHBGSDZkdEs1TXlzaFBTaEJnRzJvdlFPLWZ1cHVoc1lPLVdtMHRjNWlXdHpMRVdWS0FpZWRERHN4aS1kVHZ1LUVTMTdFNVJvUXl1ajcwQzhqRDZWOHRSajFqZFJKS2lpNnpINzNadlMzdWNMRQ?oc=5" targe…

Google News ue, 30 Dec 2025

PAVmed Announces Reverse Stock Split - PR Newswire

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNdWFwWWZQRUtOUndpYUpMZzh6anJlOUxJUGtLdHVHRjhCZVJLaFNfN3k5SDJReDNfOUlsNjdMV0hoYmZlN3BKYWhranhCWDVFQ2xhbzJPdEJ6OGZwdXh3ckE3TndfYlBkSzVUM2NaWDhQbnA3RUVaSlU3SEtPSHZwZk5zUjYyQm1HRkowdn…

MED — Frequently Asked Questions

What is the current share price of Medifast, Inc. (MED)?

As of 2026-07-14 21:23 PDT, Medifast, Inc. (MED) trades at $10.61 on NYSE. Its 52-week range is $9.53 to $15.21.

What is the market capitalisation of MED?

Medifast, Inc. (MED) has a market capitalisation of $117.97M on NYSE.

What is the P/E ratio of MED?

MED trades at a trailing price-to-earnings (P/E) ratio of -5.83. The industry average P/E is 22.82. Its price-to-book (P/B) ratio is 0.62.

What is the return on equity (ROE) of MED?

MED has a return on equity (ROE) of -9.80%. Its return on capital employed (ROCE) is -6.93%.

Is MED a good stock to buy?

This page provides a data-driven analysis of Medifast, Inc. (MED), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Consumer Cyclical Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Medifast, Inc. MED R2K

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

A Look Back at Personal Care Stocks’ Q1 Earnings: Medifast (NYSE:MED) Vs The Rest Of The Pack - Yahoo Finance

Medifast Inc (NYSE: MED) director details indirect fund-held share ownership in Form 3/A - Stock Titan

3 Reasons MED is Risky and 1 Stock to Buy Instead - StockStory

Medical Technology Stocks: Innovation Endures as Valuations Reset - AllianceBernstein

Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025’s Largest Hong Kong Biotech IPO - Insilico Medicine

PAVmed Announces Reverse Stock Split - PR Newswire

MED — Frequently Asked Questions

What is the current share price of Medifast, Inc. (MED)?

What is the market capitalisation of MED?

What is the P/E ratio of MED?

What is the return on equity (ROE) of MED?

Is MED a good stock to buy?

Explore More